Wall Street analysts expect that Cellectis SA (NASDAQ:CLLS) will report earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Cellectis’ earnings. Cellectis reported earnings per share of ($0.73) in the same quarter last year, which suggests a positive year-over-year growth rate of 72.6%. The company is expected to report its next earnings report on Monday, November 12th.
According to Zacks, analysts expect that Cellectis will report full-year earnings of ($0.78) per share for the current year. For the next financial year, analysts expect that the company will post earnings of ($1.14) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Cellectis.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.45. The company had revenue of $8.34 million during the quarter, compared to analyst estimates of $9.43 million. Cellectis had a negative net margin of 281.38% and a negative return on equity of 25.46%.
Several research firms have recently weighed in on CLLS. ValuEngine lowered shares of Cellectis from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Barclays assumed coverage on shares of Cellectis in a report on Monday, July 16th. They set an “overweight” rating and a $50.00 price objective for the company. Oppenheimer increased their price target on shares of Cellectis from $40.00 to $44.00 and gave the company an “outperform” rating in a research note on Tuesday, June 12th. Zacks Investment Research cut shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 10th. Finally, BidaskClub cut shares of Cellectis from a “sell” rating to a “strong sell” rating in a research note on Friday, September 7th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $49.20.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Cellectis by 18.0% during the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after purchasing an additional 647,164 shares during the last quarter. Bain Capital Public Equity Management LLC bought a new stake in shares of Cellectis during the second quarter valued at approximately $3,098,000. Millennium Management LLC grew its stake in shares of Cellectis by 223.1% during the second quarter. Millennium Management LLC now owns 145,563 shares of the biotechnology company’s stock valued at $4,118,000 after purchasing an additional 100,515 shares during the last quarter. Nexthera Capital LP grew its stake in shares of Cellectis by 64.7% during the second quarter. Nexthera Capital LP now owns 548,212 shares of the biotechnology company’s stock valued at $15,509,000 after purchasing an additional 215,458 shares during the last quarter. Finally, Adalta Capital Management LLC bought a new stake in shares of Cellectis during the second quarter valued at approximately $620,000. 27.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ CLLS traded down $0.61 during mid-day trading on Wednesday, hitting $27.75. 4,530 shares of the stock were exchanged, compared to its average volume of 208,996. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -10.20 and a beta of 1.84. Cellectis has a twelve month low of $22.62 and a twelve month high of $38.85.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Featured Article: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.